Chronic kidney disease Constipation Chronic Kidney Disease Protein-Bound Uremic Toxins Indoxyl Sulfate p-Cresyl Sulfate Lactulose Sennosides
Conditions
Interventions
Participants receive oral lactulose at a dose of 30 mL once daily at bedtime for 12 weeks. Lactulose acts as an osmotic laxative and prebiotic, aiming to reduce protein-bound uremic toxins in patients
Experimental Drug,Experimental Drug
Sponsors
Thai red cross society
Faculty of medicine, Chulalongkorn university
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with chronic kidney disease stage 4-5 who have not yet received renal replacement therapy 2. Presence of constipation, defined by the Bristol Stool Scale types 1-2 together with a bowel movement frequency of fewer than three times per week for at least three months.
Exclusion criteria
Exclusion criteria: 1. Use of lactulose or sennoside within the previous one month. 2. History of coronary artery disease. 3. Presence of liver cirrhosis. 4. History of bowel surgery or presence of short bowel syndrome. 5. Use of systemic antibiotics within the previous one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protein-bound uremic toxins Baseline and Week 12 Change from baseline in serum indoxyl sulfate and p-cresyl sulfate measured by high-performance liquid chromatography | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in estimated glomerular filtration rate Baseline and Week 12 Change from baseline in estimated glomerular filtration rate calculated using the CKD-EPI equation,Change in blood urea nitrogen Baseline and Week 12 Change from baseline in blood urea nitrogen measured by standard laboratory methods | — |
Countries
Thailand
Contacts
Public ContactJarukit Kamnuanpol
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed